-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADVC-001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADVC-001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ADVC-001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:ADVC-001 is under...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H2, 2018" provides an overview of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...